Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001390478-26-000020
What the release said
On November 12, 2026, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2026 and providing a corporate update.
SELLAS reported a net loss of $10.1 million for the third quarter of 2026, or $0.05 per share, compared with a net loss of $6.8 million, or $0.06 per share, for the third quarter of 2025.¶2
Research and development expenses were $7.0 million and general and administrative expenses were $4.3 million for the third quarter of 2026, compared with $4.2 million and $2.9 million for the same period in 2025.¶3¶4
Cash and cash equivalents totaled approximately $134.7 million as of September 30, 2026.¶5
The company expects to announce topline primary endpoint results of the Phase 3 REGAL trial of GPS in November 2026 following the pre-specified 80th event.¶6¶7
Phase 2 data for tambiciclib (SLS009) in relapsed or refractory AML, showing a 54% ORR in monocytic AML and a 57% ORR in TP53-mutated AML, will be presented at ASH on December 12–15, 2026.¶8
- Net loss, third quarter 2026
- $10.1 million Compared with $6.8 million for the third quarter of 2025¶2
- Basic and diluted loss per share, third quarter 2026
- $0.05 Compared with $0.06 for the third quarter of 2025¶2
- Research and development expenses, third quarter 2026
- $7.0 million Compared with $4.2 million for the same period in 2025¶3
- General and administrative expenses, third quarter 2026
- $4.3 million Compared with $2.9 million for the same period in 2025¶4
- Cash and cash equivalents
- $134.7 million As of September 30, 2026¶5
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | $0.00 |
| Net Income | -$10.09M | -$6.79M | -$7.11M | -$9.27M |
| EPS Diluted | -$0.05 | -$0.06 | -$0.10 | -$0.33 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR